People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2018 |
| Aura Biosciences, Inc. | — | Biotechnology | Series C | $198.2M | $2.5B | 2015 |
| Lysosomal Therapeutics, Inc. | — | Biotechnology | Series B | $38.0M | $39.7M | 2014 |
Peter Wirth at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Wirth on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Robert Nelsen | 1 | 22 |
| Amir Nashat | 1 | 14 |
| Bruce Booth | 1 | 12 |
| Peter B. Finn | 1 | 11 |
| Srinivas Akkaraju | 1 | 10 |
| Clay Thorp | 1 | 10 |
| Vicki Sato | 1 | 6 |
| Daniel Geffken | 1 | 6 |
| Douglas Cole | 1 | 5 |
| Casper Breum | 1 | 5 |
| Noubar B Afeyan | 1 | 5 |
| Robert Carpenter | 1 | 5 |
| Steven E. Hall | 1 | 4 |
| Jorge Conde | 1 | 4 |
| Lawrence C. Best | 1 | 4 |
| BERNARD DAVITIAN | 1 | 4 |
| Stephane Bancel | 1 | 4 |
| Pedro Granadillo | 1 | 3 |
| James E. Bradner | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.